Full-Time

Market Access Lead

Confirmed live in the last 24 hours

Deadline 7/4/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

Compensation Overview

$125.3k - $181k/yr

Senior

Toronto, ON, Canada

Hybrid role requiring some in-office presence and travel primarily within Canada.

Category
Financial Consulting
Consulting
Required Skills
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • University degree, master’s degree in health sciences, business, and/or health economics would be an asset
  • +5 years' experience in the pharmaceutical industry in market access or in the development of negotiation or HEOR strategies for payers
  • Expertise in maneuvering within the government system, especially within the provincial drug plans and health agencies
  • Leading teams in order to achieve successful negotiations
  • Expertise in specialty care medicine with experience in the HTA processes and formulary listing processes
  • In-depth knowledge and understanding of the healthcare and reimbursement landscape
  • Understanding of strategic interplays that influence payer decisions
  • Well established stakeholder/political/influencer network within the provincial public and private payer markets
  • Strategic influencing and negotiation skills
  • Strong personal leadership
  • Excellent analytical skills
  • Strategy agility and strong business acumen
  • Organizational agility and courage
  • Project and vendor management
  • Ability to deal with ambiguity
  • Excellent interpersonal, communication (both oral and written) skills
  • Ability to lead teams
  • Collaborative
  • English (Bilingual would be an asset)
  • Understanding of various health system databases (i.e. IQVIA, pharmacy claims databases) and competency with Microsoft (i.e. Excel, PowerPoint)
Responsibilities
  • Per brand/offering, develop, maintain and continuously optimize the market access strategy and payer value proposition throughout its lifecycle
  • Formulate evidence-based payer value propositions based on robust understanding of payers and their decision-making systems
  • Define the overall payer strategy to execute the reimbursement and/or tendering strategy, inclusive of the integration of required stakeholders, policy, KOL influencing activities and all relevant functions
  • Proactively define the required strategies to shape and influence the desired marketplace, and facilitate the implementation of the plan in advance of anticipated customer needs
  • Define business growth opportunities within Key Payer Accounts, key factors driving customers’ decisions, and potential solutions to capitalize and optimize payer access as identified from understanding payer needs
  • Ensure flawless execution of reimbursement submissions and rebuttals at HTAs, and provincial/hospital levels by building high quality value dossiers with medical, health economics, marketing and provincial payer managers to include clinical dossier, health economic budget impact models and any evidence that can impact decisions
  • Support activities within the key therapeutic areas aimed at continuous demonstration and communication of the value of Sanofi offerings to the payers
  • Utilizing customer insights and input, elaborate new and innovative strategies including product listing agreements (PLAs) with federal and provincial drug plans and/or cancer agencies to optimize reimbursement of Sanofi products and offerings in collaboration with the provincial payer manager, business intelligence, health economics, marketing and pricing to optimize revenue for the brands
  • Working with external expertise, early input into the Health Economics strategy to support the payer value proposition
  • Strong understanding and intelligence of the Canadian payer environment (public and private), CDA, INESSS and provincial decision-making processes
  • Work with the Pricing team to develop sustainable business and achieve local and global approval of the pricing strategy for new products taking into account the policy and politic environment (payers, pCPA, PMPRB), the reimbursement challenges and financial considerations
  • Collaborate in the development of stakeholder engagement plans to facilitate activities which enable maximal private and public coverage with expedited provincial reimbursement
  • Work with product managers and financial analysts to generate forecasts, including market access projections and product penetration analysis. Ensure validation with provincial and private payer managers
  • Work with the global/North American organization to ensure alignment of strategies/share best practices
Desired Qualifications
  • Bilingual would be an asset

Sanofi provides healthcare solutions through its focus on pharmaceuticals and biotechnology. The company develops treatments and vaccines aimed at addressing medical needs in areas like immunology, oncology, and rare diseases. Sanofi's products work by utilizing advanced research and development to create effective therapies and vaccines that improve patient health. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and a diverse portfolio that includes prescription medicines and over-the-counter products. The company aims to enhance health outcomes and quality of life for people globally by ensuring that its products are safe, effective, and accessible.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Q1 2025 profit grew by 20%, indicating strong financial performance.
  • The integration of AI in R&D accelerates drug discovery and reduces costs.
  • mRNA technology expansion offers new drug development opportunities for Sanofi.

What critics are saying

  • Increased competition in immunology may impact Sanofi's market share.
  • Potential regulatory delays could affect the launch of new drugs like tolebrutinib.
  • Acquisitions may lead to integration challenges and operational disruptions.

What makes Sanofi unique

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The on-body injector for Sarclisa offers a novel delivery method for multiple myeloma.
  • Dupixent's approval for chronic spontaneous urticaria marks a significant therapeutic advancement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...

Quantis
Apr 24th, 2025
Innate Pharma: €15M Investment by Sanofi

Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.